Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
NETWORK
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map
CUSTOM DERMATOLOGY SEARCH:
Loading

Update on Drugs and Drug News - Number 4 1999



Class Name/Company Approval Dates and Comments

Anticancer

Methoxsalen
Uvadex
Therakos

In April, 1999, the FDA approved this drug for extracorporeal administration with the UVAR Photophoresis system in the palliative treatment of skin manifestations of cutaneous T-cell lymphoma that are unresponsive to other forms of treatment.

Diabetic ulcers

Becaplermin 0.01%
Regranex®
Janssen-Ortho

FDA approved for the treatment of full thickness, lower extremity diabetic ulcers.

Metastatic melanoma

Aldesleukin
Proleukin®
Chiron

Approved in February, 1999, by the US FDA for the treatment of metastatic melanoma in adults.

Post-herpetic neuralgia

Post-herpetic neuralgia
Lidoderm® patch
Endo Pharmaceuticals

Approved in March, 1999, by the US FDA to treat the pain associated with post-herpetic neuralgia (PHN) complication of shingles. This is the first product approved by the FDA for the treatment of PHN.

Anti-inflammatory dermatoses

Betamethasone valerate foam
Luxiq® 0.12%
Connetics Corporation

Approved in March, 1999, by the US FDA for the relief of inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses of the scalp.

Drug News

Anticancer

Paclitaxel
Taxop®
Bristol-Myers Squibb Co.

Nail disorders or changes may occur more often than was at first thought. These changes can include discoloring, nailthickening, onycholysis, and paronychia.

Dietary supplements

Labels must now list all ingredients in order of quantity, suggested serving, percent daily value and amount of calories. Vitamin and mineral product labels must state the quantity of specific nutrients and herbal products must specify the actual plant parts used.

Malignant melanoma

Temozolomide
Temodal®
Schering-Plough

The FDA’s Oncologic Drugs Advisory Committee recommended against approval of temozolomide because of an inability to demonstrate any superiority over dacarbazine for this condition.

Tinea pedis

Terbinafine HCl cream 1%
Lamisil®
Novartis

In March, 1999, the FDA approved the switch from prescription status to over-the-counter availability of terbinafine cream for tinea pedis.


In this issue:

  1. Focus on Diane-35®
  2. Psoriasis Treatments Under Development
  3. Update on Drugs and Drug News - Number 4 1999